HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

By
Cansu Yerinde
Jacqueline Keye
Hsiang-Jung Hsiao
Sibel Durlanik
Inka Freise
Franziska Nowak
Marilena Letizia
Stephan Schlickeiser
Benedikt Obermayer
Adrian Huck
Marie Friedrich
Hao Wu
Désirée Kunkel
Anja A. Kühl
Sebastian Bauer
Andreas Thiel
Ahmed N. Hegazy
Britta Siegmund
Rainer Glauben
Carl Weidinger
May 12, 2026
0 min

Frontiers In Immunology

1

HDAC7 is crucial for the differentiation and functionality of peripheral CD8+ T cells, influencing immune responses against tumors and viruses.
2

Absence of HDAC7 in CD8+ T cells results in increased immune checkpoint molecules, apoptosis, and disrupted glutamine homeostasis.
3

HDAC7 deficiency compromises anti-tumor immune responses in lymphoma models and impairs CD8+ T cell memory recall during viral infections.
4

The study highlights the role of HDAC7 in regulating cellular exhaustion and apoptosis in CD8+ T cells, impacting their immune efficacy.
5

Findings suggest that HDAC7 modulates metabolic fitness and viability of CD8+ T cells, essential for effective anti-viral and anti-tumor immunity.

Original Source(s)

Frontiers In Immunology

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

by Cansu Yerinde, Jacqueline Keye, Hsiang-Jung Hsiao, Sibel Durlanik, Inka Freise, Franziska Nowak, Marilena Letizia, Stephan Schlickeiser, Benedikt Obermayer, Adrian Huck, Marie Friedrich, Hao Wu, Désirée Kunkel, Anja A. Kühl, Sebastian Bauer, Andreas Thiel, Ahmed N. Hegazy, Britta Siegmund, Rainer Glauben, Carl Weidinger
May 12, 2026

Related Content

Frontiers In Hematology

Mechanisms of kinase inhibitor resistance in subtypes of cutaneous T-cell lymphomas

Fox Chase Cancer Center

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.